FINV
FINAL DECISION TRANSACTION PROCESSED BY IB
04/18/2022
Back to search
Official data from USPTO
ZOLGENSMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
28
Latest update
04/18/2022
Trademark type
Combined
Nice classes
5
Filing date
01/18/2021
Registration date
10/12/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/12/2021
Last transaction
10/12/2021
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
CH
Examiner
MAHMOUDI, MARIAM AZIZ
Law office
M60
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of a small section of a DNA helix above and to the left of the letter "Z" in the word "ZOLGENSMA", which is in lowercase; "ZOLGEN" and the left side and middle bars of the helix are dark magenta and "SMA" and the right side of the helix are green.
Holders and representatives
Holders
NOVARTIS AG
Representatives
Maury M. Tepper, III Tepper & Eyster, PLLC
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune systemthe metabolic systemthe endocrine systemthe musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma
Publications
History of USPTO decisions and trademark events.
28 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
03/29/2022
FIMP
FINAL DISPOSITION PROCESSED
03/29/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
01/12/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
10/12/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/27/2021
PUBO
PUBLISHED FOR OPPOSITION
07/27/2021
RFNT
REFUSAL PROCESSED BY IB
07/11/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/07/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/22/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/18/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/18/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/18/2021
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
06/17/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/17/2021
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
06/17/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
06/17/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
06/17/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
06/17/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
05/27/2021
RFRR
REFUSAL PROCESSED BY MPU
05/27/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
05/26/2021
CNRT
NON-FINAL ACTION WRITTEN
05/25/2021
DOCK
ASSIGNED TO EXAMINER
05/18/2021
MAFR
APPLICATION FILING RECEIPT MAILED
05/11/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/05/2021
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
05/04/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
04/29/2021
Continuous trademark protection
Get notified about every new filing that threatens ZOLGENSMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.